Home
BCRX
BCRX News

Latest BioCryst Pharmaceuticals Inc. (BCRX) News on October 9, 2025

BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market

Insider Monkey

5 days ago

BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 days ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

8 days ago

BioCryst Pharmaceuticals Closes $250 Million Sale of Orladeyo Business in Europe

MT Newswires

8 days ago

Evercore ISI Downgrades BioCryst Pharmaceuticals to In Line From Outperform, Lifts Price Target to $8 From $12

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

GlobeNewswire

8 days ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

Investing.com

a month ago

BofA lists 13 SMID cap stocks that could rebound

BioCryst to Present at Upcoming Investor Conference

GlobeNewswire

2 months ago

BioCryst to Present at Upcoming Investor Conference

MT Newswires

3 months ago

Wedbush Raises Price Target on BioCryst Pharmaceuticals to $18 From $16, Maintains Outperform Rating

MT Newswires

3 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

3 months ago

Sector Update: Health Care Stocks Mixed Friday Afternoon

MT Newswires

3 months ago

Sector Update: Health Care Stocks Edge Higher Premarket Friday

MT Newswires

3 months ago

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid China Trade Deal Optimism

MT Newswires

3 months ago

BioCryst Pharmaceuticals to Sell European Orladeyo Business for up to $264 Million

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

GlobeNewswire

3 months ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB

Zacks

3 months ago

Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB

BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks

3 months ago

BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?

Zacks

4 months ago

Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

GlobeNewswire

4 months ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

MT Newswires

4 months ago

Sector Update: Health Care Stocks Lean Lower Premarket Friday

MT Newswires

4 months ago

BioCryst Pharmaceuticals Receives Approval for Orladeyo in Colombia

ORLADEYO® (berotralstat) Approved in Colombia

GlobeNewswire

4 months ago

ORLADEYO® (berotralstat) Approved in Colombia

United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?

Zacks

4 months ago

United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?

MT Newswires

4 months ago

BioCryst Pharmaceuticals' Hereditary Angioedema Drug Approved for Reimbursement in Netherlands

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

GlobeNewswire

4 months ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?

Zacks

4 months ago

BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?

Best Momentum Stock to Buy for June 4th

Zacks

4 months ago

Best Momentum Stock to Buy for June 4th

New Strong Buy Stocks for June 4th

Zacks

4 months ago

New Strong Buy Stocks for June 4th

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

GlobeNewswire

4 months ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

GlobeNewswire

4 months ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?

Zacks

4 months ago

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire

4 months ago

BioCryst to Present at Upcoming Investor Conferences

Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade

Zacks

4 months ago

Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade

MT Newswires

5 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Friday

MT Newswires

5 months ago

BioCryst Says Orladeyo Prompted 'Significant' Drop Hereditary Angioedema Attacks in Study

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

GlobeNewswire

5 months ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

FDA awards BioCryst’s Orladeyo NDA for paediatric HAE

Pharmaceutical Technology

5 months ago

FDA awards BioCryst’s Orladeyo NDA for paediatric HAE

MT Newswires

5 months ago

BioCryst Pharmaceuticals Says FDA Grants Priority Review for Orladeyo in Children

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

GlobeNewswire

5 months ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

Best Momentum Stocks to Buy for May 9th

Zacks

5 months ago

Best Momentum Stocks to Buy for May 9th

Why BioCryst (BCRX) Might be Well Poised for a Surge

Zacks

5 months ago

Why BioCryst (BCRX) Might be Well Poised for a Surge

What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now?

Zacks

5 months ago

What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now?

Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?

Zacks

5 months ago

Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Simply Wall St.

5 months ago

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

MT Newswires

5 months ago

RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating

Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday

Insider Monkey

5 months ago

Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday

BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ...

GuruFocus.com

5 months ago

BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ...

Thomson Reuters StreetEvents

5 months ago

Q1 2025 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1

Zacks

5 months ago

BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1

MT Newswires

5 months ago

BioCryst Pharmaceuticals Reports Breakeven in Q1, Higher Revenue; Shares up Pre-Bell

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

5 months ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

High Growth Tech Stocks To Watch In The US May 2025

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In The US May 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Appoints Steve Frank to Board of Directors

GlobeNewswire

5 months ago

BioCryst Appoints Steve Frank to Board of Directors

Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

5 months ago

Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire

5 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

5 months ago

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BioCryst to Report First Quarter 2025 Financial Results on May 5

GlobeNewswire

6 months ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

Zacks

6 months ago

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

MT Newswires

6 months ago

BioCryst Pharmaceuticals CEO Takes On Finance Duties on Interim Basis

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at Upcoming Investor Conference

GlobeNewswire

6 months ago

BioCryst to Present at Upcoming Investor Conference

High Growth Tech Stocks In The US Market With Promising Potential

Simply Wall St.

6 months ago

High Growth Tech Stocks In The US Market With Promising Potential

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%

Simply Wall St.

7 months ago

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

7 months ago

BioCryst Pharmaceuticals CFO Anthony Doyle to Step Down

Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?

Insider Monkey

7 months ago

Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?

BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks

7 months ago

BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher

Zacks

7 months ago

Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher

Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know

Zacks

7 months ago

Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know

Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results

Simply Wall St.

7 months ago

Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results

Company News for Feb 25, 2025

Zacks

7 months ago

Company News for Feb 25, 2025

MT Newswires

7 months ago

RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating

BioCryst Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

7 months ago

BioCryst Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Thomson Reuters StreetEvents

7 months ago

Q4 2024 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ...

GuruFocus.com

7 months ago

BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ...

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

Motley Fool

7 months ago

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript

Motley Fool

7 months ago

BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

Zacks

8 months ago

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

MT Newswires

8 months ago

BioCryst Says Interim Data Show Orladeyo Reduced Attack Rates in Pediatric Patients With Hereditary Angioedema

MT Newswires

8 months ago

BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows, Revenue Rises

Associated Press Finance

8 months ago

BioCryst: Q4 Earnings Snapshot

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

GlobeNewswire

8 months ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

GlobeNewswire

8 months ago

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire

8 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

8 months ago

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

MT Newswires

8 months ago

BioCryst Says Orladeyo Recommended for Hereditary Angioedema Prevention in Portugal

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

GlobeNewswire

8 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

8 months ago

Exploring Three High Growth Tech Stocks In The United States

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

GlobeNewswire

8 months ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

GlobeNewswire

8 months ago

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock

Simply Wall St.

8 months ago

Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock

BioCryst price target raised to $12 from $10 at Evercore ISI

TipRanks

9 months ago

BioCryst price target raised to $12 from $10 at Evercore ISI

Exploring High Growth Tech Stocks In January 2025

Simply Wall St.

9 months ago

Exploring High Growth Tech Stocks In January 2025

MT Newswires

9 months ago

BioCryst Pharmaceuticals Preliminary Q4 Revenue Rises

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

GlobeNewswire

9 months ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

9 months ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%

Simply Wall St.

9 months ago

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%

Share on Social Networks: